Holocene Advisors LP Grows Stock Position in Edwards Lifesciences Corporation $EW

by · The Markets Daily

Holocene Advisors LP grew its holdings in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 35.2% in the 2nd quarter, Holdings Channel.com reports. The fund owned 4,703,977 shares of the medical research company’s stock after buying an additional 1,223,460 shares during the period. Edwards Lifesciences makes up 0.9% of Holocene Advisors LP’s holdings, making the stock its 18th biggest holding. Holocene Advisors LP’s holdings in Edwards Lifesciences were worth $367,898,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rosenberg Matthew Hamilton acquired a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $28,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the first quarter worth $26,000. NewSquare Capital LLC lifted its stake in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the period. SouthState Corp purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at $27,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $40,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $83.06 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The stock has a market capitalization of $48.20 billion, a price-to-earnings ratio of 35.80, a PEG ratio of 3.79 and a beta of 0.97. The firm’s 50 day simple moving average is $81.62 and its 200-day simple moving average is $79.01. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the sale, the vice president owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,465 shares of company stock worth $3,804,610 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on EW shares. Oppenheimer cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Wells Fargo & Company restated an “overweight” rating and issued a $96.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research note on Friday, December 5th. Robert W. Baird upped their target price on Edwards Lifesciences from $83.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, December 5th. The Goldman Sachs Group set a $104.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.30.

View Our Latest Research Report on EW

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).